alanine has been researched along with Amnesia in 1 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Amnesia: Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Primary outcome measures were adverse events, plasma and cerebrospinal fluid Abeta levels, vital signs, electrocardiographic data, and laboratory safety test results." | 2.73 | Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. ( Aisen, PS; Becerra, L; Clark, CM; Dean, RA; Farlow, MR; Fleisher, AS; Galvin, JE; Peskind, ER; Quinn, JF; Raman, R; Sherzai, A; Siemers, ER; Sowell, BB; Thal, LJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fleisher, AS | 1 |
| Raman, R | 1 |
| Siemers, ER | 1 |
| Becerra, L | 1 |
| Clark, CM | 1 |
| Dean, RA | 1 |
| Farlow, MR | 1 |
| Galvin, JE | 1 |
| Peskind, ER | 1 |
| Quinn, JF | 1 |
| Sherzai, A | 1 |
| Sowell, BB | 1 |
| Aisen, PS | 1 |
| Thal, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| LY450139: Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimer's Disease[NCT00244322] | Phase 2 | 45 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for alanine and Amnesia
| Article | Year |
|---|---|
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Amyloid Precurs | 2008 |